sécurité sociale – Déremboursement de nombreuses molécules dites « onéreuses »

This written question concerns the potential de-reimbursement of several expensive medicines from social security coverage in France. It seeks clarification on the criteria and impact of such decisions on patient access to treatments. The question highlights concerns about the financial sustainability of the healthcare system and the accessibility of innovative but costly treatments for patients.